Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) EBT Margin (2016 - 2025)

Historic EBT Margin for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to 112.26%.

  • Ultragenyx Pharmaceutical's EBT Margin fell 167600.0% to 112.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.46%, marking a year-over-year increase of 158800.0%. This contributed to the annual value of 101.31% for FY2024, which is 388100.0% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's EBT Margin stood at 112.26%, which was down 167600.0% from 68.47% recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's EBT Margin's 5-year high stood at 68.47% during Q2 2025, with a 5-year trough of 263.3% in Q3 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's median EBT Margin value was 140.23% (recorded in 2021), while the average stood at 135.62%.
  • Data for Ultragenyx Pharmaceutical's EBT Margin shows a peak YoY increase of 1901000bps (in 2021) and a maximum YoY decrease of -1819300bps (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's EBT Margin stood at 149.63% in 2021, then dropped by 0bps to 149.95% in 2022, then surged by 34bps to 99.61% in 2023, then rose by 19bps to 80.91% in 2024, then plummeted by -39bps to 112.26% in 2025.
  • Its EBT Margin stands at 112.26% for Q3 2025, versus 68.47% for Q2 2025 and 107.52% for Q1 2025.